Publication

Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway.

Authors not recorded

Cell Death Dis2021PMID 34247201PMC8272721stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (7)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 7

cancerLung Non-Small Cell Carcinomacivic_curation1.00
cancerPancreatic Ductal Adenocarcinomacivic_curation1.00
drugNSC84167civic_curation1.00
geneKEAP1civic_curation1.00
geneNQO1civic_curation1.00
variantKEAP1 Mutationcivic_curation1.00
variantNQO1 Overexpressioncivic_curation1.00

Curated evidence

Evidence citing this paper (2)

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KEAP1 Mutation1
NSC84167	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID12575 In non–small cell lung cancer (NSCLC) models, KEAP1-mutant cell lines (H838, H460) exhibited strong sensitivity to NSC84167 (NSLC01) in MTT cell viability assays, with IC₅₀ values well below 1 µM, whi… (full text at CIViC) PMID 34247201 · Dai et al., 2021 · Open in CIViC	civic
NQO1 Overexpression1
NSC84167	Pancreatic Ductal Adenocarcinoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID12560 In preclinical pancreatic ductal adenocarcinoma (PDAC) models with high NQ01 expression, which indicates the NFE2L2 (NRF2) pathway activation, the small molecule NSC84167 (NSLC01, 50 mg/kg) selectivel… (full text at CIViC) PMID 34247201 · Dai et al., 2021 · Open in CIViC	civic